← NOVARTIS AG

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $49.4b $50.1b $53.2b $48.7b $49.9b $52.9b $51.8b $46.7b $51.7b $56.7b
Net sales from continuing operations $48.5b $49.1b $51.9b $47.5b $48.7b $51.6b $50.5b $45.4b $50.3b $54.5b
Revenue From Interest $43.0m $110.0m $294.0m $245.0m $91.0m $71.0m $379.0m $627.0m $568.0m $373.0m
Cost of Goods and Services Sold $17.5b $17.2b $18.4b $14.4b $15.1b $15.9b $15.5b $12.5b $12.8b $13.7b
Cost of goods sold ($17.5b) ($17.2b) ($18.4b) ($14.4b) ($15.1b) ($15.9b) ($15.5b) ($12.5b) ($12.8b) ($13.7b)
Gross profit from continuing operations $31.9b $33.0b $34.8b $34.3b $34.8b $37.0b $36.3b $34.2b $38.9b $43.0b
Gross Profit $31.9b $33.0b $34.8b $34.3b $34.8b $37.0b $36.3b $34.2b $38.9b $43.0b
Research and development $9.0b $9.0b $9.1b $9.4b $9.0b $9.5b $10.0b $11.4b $10.0b $11.2b
Selling, general and administration ($14.2b) ($15.0b) ($16.5b) ($14.4b) ($14.2b) ($14.9b) ($14.3b) ($12.5b) ($12.6b) ($13.2b)
Operating expenses:
Additional Financial Items
Applicable Tax Rate $0 $0 $0 — — — $0 $0 $0 $0
Average Effective Tax Rate $0 $0 $0 — — — $0 $0 $0 $0
Depreciation Right of Use Assets — — — ($305.0m) $330.0m $318.0m $300.0m — — $276.0m
Gain on distribution of Sandoz Group AG to Novartis AG shareholders — — — $4.7b — — — $5.9b — —
Income taxes ($1.1b) ($1.3b) ($1.2b) ($1.8b) ($1.8b) ($2.1b) ($1.4b) ($551.0m) ($1.7b) ($2.4b)
Loss from associated companies $703.0m $1.1b $6.4b $659.0m $673.0m $15.3b ($9.0m) ($13.0m) ($38.0m) ($12.0m)
Net income from continuing operations $6.7b $7.7b $12.6b $7.1b $8.1b $24.0b $6.0b $8.6b $11.9b $14.0b
Net income from discontinued operations — $204.0m ($186.0m) $4.6b — $1.1b $906.0m $6.3b — —
Net income from discontinued operations before gain on distribution — $204.0m ($186.0m) ($101.0m) — $1.1b $906.0m $422.0m — —
Non-controlling interests ($14.0m) $0 $3.0m $5.0m ($1.0m) ($3.0m) $0 $4.0m ($2.0m) ($17.0m)
Operating income from continuing operations $8.3b $8.6b $8.2b $9.1b $10.2b $11.7b $9.2b $9.8b $14.5b $17.6b
Other Income $1.9b $2.0b $1.7b $2.0b $1.7b $1.9b $805.0m $1.8b $1.2b $1.5b
Other revenues $918.0m $1.0b $1.3b $1.2b $1.2b $1.3b $1.3b $1.2b $1.4b $2.1b
Profit Loss Attributable To Noncontrolling Interests ($14.0m) $0 $3.0m $5.0m ($1.0m) ($3.0m) $0 $4.0m ($2.0m) ($17.0m)
Profit Loss Attributable To Owners Of Parent $6.7b $7.7b $12.6b $11.7b $8.1b $24.0b $7.0b $14.8b $11.9b $14.0b
Profit Loss Before Tax $7.8b $9.0b $13.8b $8.9b $9.9b $26.1b $8.4b $9.1b $13.6b $16.4b
Profit Loss From Operating Activities $8.3b $8.6b $8.2b $9.1b $10.2b $11.7b $9.2b $9.8b $14.5b $17.6b
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method $703.0m $1.1b $6.4b $659.0m $673.0m $15.3b ($9.0m) ($13.0m) ($38.0m) ($12.0m)
Shareholders of Novartis AG $6.7b $7.7b $12.6b $11.7b $8.1b $24.0b $7.0b $14.8b $11.9b $14.0b
Income before taxes from continuing operations $7.8b $9.0b $13.8b $8.9b $9.9b $26.1b $8.4b $9.1b $13.6b $16.4b
Net income — $7.7b $12.6b $11.7b $8.1b $24.0b $7.0b $14.9b $11.9b $14.0b
Basic Earnings (Loss) Per Share $2.82 $3.28 $5.44 $5.12 $3.55 $10.71 $3.19 $7.15 $5.92 $7.21
Basic earnings per share, Continuing operations — $3.20 $5.52 $3.12 $3.55 $10.71 $2.77 $4.13 $5.92 $7.21
Basic earnings per share, Discontinued operations — $0.08 ($0.08) $2.00 — $0.49 $0.42 $3.02 — —
Diluted Earnings (Loss) Per Share $2.80 $3.25 $5.38 $5.06 $3.52 $10.63 $3.17 $7.10 $5.87 $7.15
Diluted earnings per share, Continuing operations — $3.17 $5.46 $3.08 $3.52 $10.63 $2.76 $4.10 $5.87 $7.15
Diluted earnings per share, Discontinued operations — $0.08 ($0.08) $1.98 — $0.49 $0.41 $3.00 — —
Administrative Expense $2.2b $2.1b — — — — — — — —
Current Tax Expense (Income) — — $1.8b — — — $2.1b $2.4b $2.4b $2.7b
Deferred Tax Expense (Income) — — ($582.0m) — — — ($655.0m) ($1.9b) ($682.0m) ($360.0m)
Deferred Tax Expense (Income) Recognised In Profit Or Loss $1.0b $760.0m $582.0m $354.0m $293.0m $309.0m $655.0m — — $360.0m
Employee Benefits Expense — — — — — — $14.9b — — $13.2b
Expense From Share-Based Payment Transactions With Employees $846.0m $924.0m $1.0b — — — $1.0b $1.1b $1.3b $1.3b
Expense Relating To Leases Of Low-Value Assets For Which Recognition Exemption Has Been Used — — — $8.0m $7.0m $7.0m $6.0m $6.0m $5.0m $2.0m
Expense Relating To Short-Term Leases For Which Recognition Exemption Has Been Used — — — $7.0m $4.0m $6.0m $3.0m $5.0m $7.0m $5.0m
Income Tax Expense Continuing Operations $1.1b $1.3b $1.2b $1.8b $1.8b $2.1b $1.4b $551.0m $1.7b $2.4b
Interest Expense $707.0m $777.0m $957.0m $850.0m $869.0m $811.0m $837.0m $855.0m $1.0b $1.1b
Interest Expense On Lease Liabilities — — — $66.0m $67.0m $62.0m $60.0m $62.0m $72.0m $76.0m
Other Finance Cost $20.0m $25.0m $33.0m $52.0m $52.0m $94.0m $194.0m $18.0m $31.0m $109.0m
Other expense ($2.3b) ($2.3b) ($2.7b) ($3.4b) ($3.2b) ($2.7b) ($3.7b) ($2.3b) ($2.9b) ($2.3b)
Other financial income and expense ($447.0m) $39.0m $185.0m $45.0m ($78.0m) ($80.0m) $20.0m $222.0m $140.0m ($136.0m)
Postemployment Benefit Expense Defined Contribution Plans — — — — — — — — — $556.0m
Selling, General and Administrative Expense — — $16.5b $14.4b $14.2b $14.9b $14.3b $12.5b $12.6b $13.2b

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.